GLPcompareGLPcompare
DrugsPricesCompareShortagesEvidenceSupplementsWatchlist
HomeShortages
Availability

GLP-1 shortage reports

Check reports for each medication, see affected presentations, and know when a current status cannot be confirmed. Refreshed daily.

Last checked · Oct 3, 2026 UTC
1reported in shortage
6 / 6statuses confirmed

Complete, recent FDA checks establish a shortage status for 6 of the 6 approved medications we track. 1 have a presentation reported in shortage. Check the FDA database for the latest source reports.

Active

Reported in shortage

Affected presentations from complete, recent FDA checks. National reporting does not establish stock at your pharmacy.

Liraglutide
GLP-1Victoza, Saxenda
In shortage (Open the FDA shortage record)
Presentation
Liraglutide, Injection, 6 mg/1 mL (NDC 0480-3667-20)
Source note
Distributed by Teva
First posted
Jul 18, 2023
Updated at source
Sep 22, 2026
View FDA presentations (10)
Checked

No shortage record returned

A complete, recent FDA search returned no matching shortage records for these medications. This is not a guarantee of pharmacy stock.

SemaglutideOzempic, Wegovy, Wegovy HD, RybelsusNo shortage reported (Check the FDA shortage database)

No shortage is listed in the latest complete FDA check. The FDA does list discontinuation notices for specific presentations.

Last complete check: Oct 3, 2026

View FDA presentations (3)

These notices concern specific presentations, not every product containing this ingredient. A current shortage and a planned discontinuation can be reported together. FDA availability notes do not confirm local pharmacy stock.

  • Rybelsus, Tablet, 3 mg (NDC 0169-4303-30)

    Planned discontinuation

Primary source: openFDA Drug Shortages · as of Oct 3, 2026

Shortage status is published by the FDA and can change daily. A drug with no reported shortage may still be constrained at an individual pharmacy, and a drug in shortage may remain dispensable in some presentations. Confirm current availability with your pharmacy.
All drugsPrice comparisonEvidenceMethodology
GLPcompare is an informational data platform, not a medical provider or pharmacy. Nothing here is medical advice, a diagnosis, or a recommendation to start, stop, or change any treatment. Data is aggregated from public sources and can be incomplete or out of date. Always confirm with a licensed clinician and the current FDA label.
GLPcompareGLPcompare

The live, fully-cited reference for the GLP-1 ecosystem. Every figure traces to its source. Informational only, not medical advice.

Product

  • Drugs
  • Prices
  • Compare
  • Shortages
  • Evidence
  • Supplements

Legal

  • Methodology
  • About
  • News
  • Price updates
  • Privacy Policy
  • Terms of Service
  • Support

Some outbound links on GLPcompare are referral links. If you sign up or buy through one, we may earn a commission at no extra cost to you. It never changes the price you pay or the underlying data. Partner status and commission rates contribute to offer and provider value scores and can change their order. Every partner is labeled. Value scores are not medical recommendations; a higher-ranked offer is not necessarily the lowest price or the right product for you.

© 2026 GLPcompare. All rights reserved.

Fazier

These notices concern specific presentations, not every product containing this ingredient. A current shortage and a planned discontinuation can be reported together. FDA availability notes do not confirm local pharmacy stock.

  • Liraglutide, Injection, 6 mg/1 mL (NDC 0480-3667-20)

    In shortage

    • FDA status: Current

      Source availability: Available

      Distributed by Teva

      Updated at source: Sep 22, 2026

  • Liraglutide, Injection, 6 mg/1 mL (NDC 0480-3667-22)

    In shortage

    • FDA status: Current

      Source availability: Available

      Distributed by Teva

      Updated at source: Sep 22, 2026

  • Liraglutide, Injection, 6 mg/1 mL (NDC 71288-563-84)

    In shortage

    • FDA status: Current

      Source availability: Available

      Updated at source: Aug 27, 2026

  • Liraglutide, Injection, 6 mg/1 mL (NDC 0143-9144-02)

    In shortage

    • FDA status: Current

      Source availability: Available

      Updated at source: Sep 18, 2026

  • Liraglutide, Injection, 6 mg/1 mL (NDC 0143-9144-03)

    In shortage

    • FDA status: Current

      Source availability: Available

      Updated at source: Sep 18, 2026

  • Saxenda, Injection, 6 mg/1 mL (NDC 0169-2800-15)

    In shortage

    • FDA status: Current

      Source availability: Limited Availability

      Reason: Discontinuation of the manufacture of the drug

      Product will be available until discontinuation in January 2027

      Updated at source: Sep 22, 2026

    • FDA status: To Be Discontinued

      Product will be available until discontinuation in January 2027; Discontinuation of the manufacture of the drug

      FDA discontinuation date: Aug 25, 2026

      Updated at source: Aug 25, 2026

  • Liraglutide, Injection, 6 mg/1 mL (NDC 0480-7250-46)

    Planned discontinuation

    • FDA status: To Be Discontinued

      Discontinuation of the manufacture of the drug

      FDA discontinuation date: May 14, 2026

      Updated at source: May 14, 2026

  • Liraglutide, Injection, 6 mg/1 mL (NDC 71288-563-85)

    In shortage

    • FDA status: Current

      Source availability: Available

      Updated at source: Aug 27, 2026

  • Victoza, Injection, 6 mg/1 mL (NDC 0169-4060-12)

    In shortage

    • FDA status: Current

      Source availability: Limited Availability

      Reason: Delay in shipping of the drug

      Estimated shortage duration: TBD

      Updated at source: Sep 22, 2026

  • Victoza, Injection, 6 mg/1 mL (NDC 0169-4060-13)

    In shortage

    • FDA status: Current

      Source availability: Limited Availability

      Reason: Delay in shipping of the drug

      Estimated shortage duration: TBD

      Updated at source: Sep 22, 2026

Source: openFDA Drug Shortages · as of Oct 3, 2026

Full drug profile

  • FDA status: To Be Discontinued

    Discontinuation of the manufacture of the drug. These products will be replaced by Ozempic (semaglutide) tablets.

    FDA discontinuation date: Jun 4, 2026

    Updated at source: Jun 4, 2026

  • Rybelsus, Tablet, 14 mg (NDC 0169-4314-30)

    Planned discontinuation

    • FDA status: To Be Discontinued

      Discontinuation of the manufacture of the drug. These products will be replaced by Ozempic (semaglutide) tablets.

      FDA discontinuation date: Jun 4, 2026

      Updated at source: Jun 4, 2026

  • Rybelsus, Tablet, 7 mg (NDC 0169-4307-30)

    Planned discontinuation

    • FDA status: To Be Discontinued

      Discontinuation of the manufacture of the drug. These products will be replaced by Ozempic (semaglutide) tablets.

      FDA discontinuation date: Jun 4, 2026

      Updated at source: Jun 4, 2026

    • TirzepatideMounjaro, ZepboundNo shortage reported (Check the FDA shortage database)

    No matching shortage record was returned in the latest complete FDA check.

    Last complete check: Oct 3, 2026

    DulaglutideTrulicityNo shortage reported (Check the FDA shortage database)

    No matching shortage record was returned in the latest complete FDA check.

    Last complete check: Oct 3, 2026

    ExenatideByetta (discontinued), Bydureon BCise (discontinued), Generic exenatideNo shortage reported (Check the FDA shortage database)

    No matching shortage record was returned in the latest complete FDA check.

    Last complete check: Oct 3, 2026

    OrforglipronFoundayoNo shortage reported (Check the FDA shortage database)

    No matching shortage record was returned in the latest complete FDA check.

    Last complete check: Oct 3, 2026